Cardiovasc Diabetol: Relative Contributions of Statin Intensity, Achieved Low Density Lipoprotein Cholesterol Levels, and Duration of Statin Therapy to Reduced Cardiovascular Risk in Type 2 Diabetes

Background: Type 2 diabetes (T2D) is often accompanied by dyslipidemia, which is characterized by elevated triglycerides (TG), low high-density lipoprotein cholesterol (HDL-C), and small, dense low-density lipoprotein cholesterol (LDL- C) increase in particles

Type 2 diabetes (T2D) is often accompanied by dyslipidemia, characterized by elevated triglycerides (TG), low high-density lipoprotein cholesterol (HDL-C), and small, dense low-density lipoprotein cholesterol (LDL-C) particles increased

Current guidelines recommend lifetime statin use in patients with type 2 diabetes (T2D), however, some patients discontinue statin therapy in clinical practice

Methods: 8937 T2D patients aged ≥40 years from the Korean National Health Insurance Service cohort (2007-2015) received statin therapy for at least 90 days

Results: Patients receiving moderate- and high-intensity statin therapy had a lower hazard ratio (HR) for MACE than patients receiving low-intensity statin therapy (HR, 0.

Table 1 Cumulative incidence of major cardiovascular events by statin intensity

Table 1 Cumulative incidence of major cardiovascular events by statin intensity

Figure 1 Cubic spline curve for adjusting hazard ratios for major cardiovascular events according to low-density lipoprotein cholesterol (LDL-C) levels (mmol/L)

Figure 1 Cubic spline curve for adjusting hazard ratios for major cardiovascular events according to low-density lipoprotein cholesterol (LDL-C) levels (mmol/L)

Figure 2 Risk of major cardiovascular events according to duration of statin therapy in patients receiving moderate- or high-intensity statin therapy

Figure 2 Risk of major cardiovascular events according to duration of statin therapy in patients receiving moderate- or high-intensity statin therapy

Figure 3 Cubic splines for hazard ratios for major cardiovascular events adjusted for duration of statin therapy

Figure 3 Cubic splines for hazard ratios for major cardiovascular events adjusted for duration of statin therapy

Figure 4 Relative importance of statin treatment duration, statin intensity, and achieved LDL-C levels as predictors of MACE

Figure 4 Relative importance of statin treatment duration, statin intensity, and achieved LDL-C levels as predictors of MACE

Duration of statin therapy is as important as, or even more important than, statin intensity or LDL-C levels achieved, and is equally important for reducing cardiovascular risk in patients with T2D

Relative contributions of statin intensity, achieved low-density lipoprotein cholesterol level, and statin therapy duration to cardiovascular risk reduction in patients with type 2 diabetes: population based cohort study.


Leave a comment here